GlobeNewsWire
07 Dec 2025, 13:05 UTC · 41w ago
Verdict
Headline takes no side. We score PRME +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Phase 1/2 clinical data for PM359 showed durable restoration of NADPH oxidase activity and early clinical benefit in two patients with chronic granulomatous disease.
So whatPositive initial efficacy and safety data in a clinical trial are primary drivers for biotech valuation and investor confidence.
More positive than 99% of claims this week
The PM359 results provide the first-in-human demonstration of the safety and efficacy of the Prime Editing platform.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 98% of claims this week
Prime Medicine reported that Prime Editing does not induce double-strand breaks, which may result in better tolerance by cells and a superior safety profile compared to other gene editing technologies.
More positive than 87% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced successful first-in-human clinical data for PM359, demonstrating safety and efficacy in treating chronic granulomatous disease.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
9h ago
−22.5%
Price is moving against the score
$2.90 vs $3.74 close before publication (Dec 5) · not market-adjusted
PRME chart →
